The University of Chicago Header Logo

Connection

Blase Polite to Humans

Back to Details
This is a "connection" page, showing publications Blase Polite has written about Humans.
Blase Polite
Connection Strength
1.235
Humans
  1. The Promise of Cancer Health Justice: How Stakeholders and the Community Can Build a Sustained and Equitable System of Cancer Care Through the Lens of Colorectal Cancer Interventions. Cancer J. 2023 Nov-Dec 01; 29(6):338-342.
    View in: PubMed
    Score: 0.030
  2. Health Equity for Black Americans: The Past Cannot Be Prologue. JCO Oncol Pract. 2021 05; 17(5):252-254.
    View in: PubMed
    Score: 0.025
  3. Improving End of Life Cancer Outcomes Through Development and Implementation of a Spiritual Care Advocate Program. Am J Hosp Palliat Care. 2021 Dec; 38(12):1441-1450.
    View in: PubMed
    Score: 0.025
  4. Oncology's "Hockey Stick" Moment for the Cost of Cancer Drugs-The Climate Is About to Change. JAMA Oncol. 2021 01 01; 7(1):25-26.
    View in: PubMed
    Score: 0.025
  5. "Let Go, Let God": A Qualitative Study Exploring Cancer Patients' Spirituality and Its Place in the Medical Setting. J Relig Health. 2020 Oct; 59(5):2341-2363.
    View in: PubMed
    Score: 0.024
  6. Bending Versus Transforming the Drug Cost Curve: A Matter of Political Will. Cancer J. 2020 Jul/Aug; 26(4):304-310.
    View in: PubMed
    Score: 0.024
  7. Formal Assessment of Teamwork Among Cancer Health Care Professionals in Three Large Tertiary Centers in Nigeria. JCO Glob Oncol. 2020 04; 6:560-568.
    View in: PubMed
    Score: 0.023
  8. Opaque Results of Federal Price Transparency Rules and State-Based Alternatives. J Oncol Pract. 2019 09; 15(9):463-464.
    View in: PubMed
    Score: 0.022
  9. Ensuring Equity and Justice in the Care and Outcomes of Patients With Cancer. JAMA. 2019 May 07; 321(17):1663-1664.
    View in: PubMed
    Score: 0.022
  10. State of Cancer Care in America: Reflections on an Inaugural Year. J Oncol Pract. 2019 04; 15(4):163-165.
    View in: PubMed
    Score: 0.022
  11. Investigation of a multimedia, computer-based approach to improve knowledge, attitudes, self-efficacy, and receptivity to cancer clinical trials among newly diagnosed patients with diverse health literacy skills. Cancer. 2019 06 15; 125(12):2066-2075.
    View in: PubMed
    Score: 0.022
  12. A New Look at the State of Cancer Care in America. J Oncol Pract. 2018 07; 14(7):397-399.
    View in: PubMed
    Score: 0.021
  13. Impact on Oncology Practices of Including Drug Costs in Bundled Payments. J Oncol Pract. 2018 05; 14(5):e259-e268.
    View in: PubMed
    Score: 0.020
  14. Association of externalizing religious and spiritual beliefs on stage of colon cancer diagnosis among black and white multicenter urban patient populations. Cancer. 2018 06 15; 124(12):2578-2587.
    View in: PubMed
    Score: 0.020
  15. A Rules-Based Algorithm to Prioritize Poor Prognosis Cancer Patients in Need of Advance Care Planning. J Palliat Med. 2018 06; 21(6):846-849.
    View in: PubMed
    Score: 0.020
  16. The Road From Theory to Reality: Illuminating the Complexity of Prospective Cancer Bundles. J Oncol Pract. 2018 02; 14(2):59-61.
    View in: PubMed
    Score: 0.020
  17. Improving the accrual of racial and ethnic minority patients in clinical trials: Time to raise the stakes. Cancer. 2017 12 15; 123(24):4752-4756.
    View in: PubMed
    Score: 0.020
  18. Blase Polite on How Disparities Research Must Move Into an Era of Action. Oncology (Williston Park). 2017 10 15; 31(10):709-10, 717.
    View in: PubMed
    Score: 0.020
  19. Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. J Clin Oncol. 2017 09 10; 35(26):3075-3082.
    View in: PubMed
    Score: 0.019
  20. Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. CA Cancer J Clin. 2017 09; 67(5):353-361.
    View in: PubMed
    Score: 0.019
  21. Charting the Future of Cancer Health Disparities Research: A Position Statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. Cancer Res. 2017 09 01; 77(17):4548-4555.
    View in: PubMed
    Score: 0.019
  22. Pursuing Value in Cancer Care: A Model in Progress. J Oncol Pract. 2017 07; 13(7):407-409.
    View in: PubMed
    Score: 0.019
  23. Implementation of Advance Care Planning in Oncology: A Review of the Literature. J Oncol Pract. 2017 10; 13(10):657-662.
    View in: PubMed
    Score: 0.019
  24. No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. J Oncol Pract. 2016 10; 12(10):e901-e911.
    View in: PubMed
    Score: 0.018
  25. A Pathway Through the Bundle Jungle. J Oncol Pract. 2016 06; 12(6):504-9.
    View in: PubMed
    Score: 0.018
  26. An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population. J Racial Ethn Health Disparities. 2017 04; 4(2):140-148.
    View in: PubMed
    Score: 0.018
  27. Oncology Pathways-Preventing a Good Idea From Going Bad. JAMA Oncol. 2016 Mar; 2(3):297-8.
    View in: PubMed
    Score: 0.018
  28. Reply to M. Thompson et Al. J Oncol Pract. 2015 May; 11(3):263-4.
    View in: PubMed
    Score: 0.016
  29. Medicare innovation center oncology care model: a toe in the water when a plunge is needed. J Oncol Pract. 2015 Mar; 11(2):117-9.
    View in: PubMed
    Score: 0.016
  30. States as the laboratory for democracy: is anybody paying attention, and does anybody care? J Clin Oncol. 2015 Mar 10; 33(8):815-6.
    View in: PubMed
    Score: 0.016
  31. Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist. Am Soc Clin Oncol Educ Book. 2015; e75-80.
    View in: PubMed
    Score: 0.016
  32. Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. Cancer. 2015 Apr 01; 121(7):1071-8.
    View in: PubMed
    Score: 0.016
  33. American Society of Clinical Oncology policy statement on medicaid reform. J Clin Oncol. 2014 Dec 20; 32(36):4162-7.
    View in: PubMed
    Score: 0.016
  34. Payment for oncolytics in the United States: a history of buy and bill and proposals for reform. J Oncol Pract. 2014 Nov; 10(6):357-62.
    View in: PubMed
    Score: 0.016
  35. The role of statins for primary prevention in non-elderly colorectal cancer patients. Anticancer Res. 2014 Sep; 34(9):5043-50.
    View in: PubMed
    Score: 0.016
  36. Achieving a deeper understanding of the implemented provisions of the Affordable Care Act. Am Soc Clin Oncol Educ Book. 2014; e472-7.
    View in: PubMed
    Score: 0.015
  37. Achieving health equity in colorectal cancer: a call to action. Am Soc Clin Oncol Educ Book. 2013; 169-73.
    View in: PubMed
    Score: 0.014
  38. Interventions to improve care related to colorectal cancer among racial and ethnic minorities: a systematic review. J Gen Intern Med. 2012 Aug; 27(8):1033-46.
    View in: PubMed
    Score: 0.014
  39. Race and subset analyses in clinical trials: time to get serious about data integration. J Natl Cancer Inst. 2011 Oct 19; 103(20):1486-8.
    View in: PubMed
    Score: 0.013
  40. Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). Cancer. 2012 Feb 15; 118(4):1083-90.
    View in: PubMed
    Score: 0.013
  41. Personalized colon cancer care in 2010. Semin Oncol. 2011 Apr; 38(2):284-308.
    View in: PubMed
    Score: 0.012
  42. Triple-negative breast cancers: a view from 10,000 feet. Cancer J. 2010 Jan-Feb; 16(1):17-22.
    View in: PubMed
    Score: 0.011
  43. Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. J Clin Oncol. 2008 Jun 01; 26(16):2659-65.
    View in: PubMed
    Score: 0.010
  44. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol. 2006 May 10; 24(14):2179-87.
    View in: PubMed
    Score: 0.009
  45. Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial. Clin Genitourin Cancer. 2006 Mar; 4(4):275-80.
    View in: PubMed
    Score: 0.009
  46. Are venous thromboembolic events associated with subsequent breast and colorectal carcinoma diagnoses in the elderly? A case-control study of Medicare beneficiaries. Cancer. 2006 Feb 15; 106(4):923-30.
    View in: PubMed
    Score: 0.009
  47. Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites. Med Clin North Am. 2005 Jul; 89(4):771-93.
    View in: PubMed
    Score: 0.008
  48. Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med. 2005; 48(1 Suppl):S166-75.
    View in: PubMed
    Score: 0.008
  49. MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 Nov 01; 31(11).
    View in: PubMed
    Score: 0.008
  50. Point/Counterpoint #2: Current Clinical Considerations With Nonoperative Management of Rectal Cancer. Cancer J. 2024 Jul-Aug 01; 30(4):256-263.
    View in: PubMed
    Score: 0.008
  51. Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clin Colorectal Cancer. 2024 Jun; 23(2):183-193.
    View in: PubMed
    Score: 0.008
  52. Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial. JAMA Netw Open. 2024 01 02; 7(1):e2350903.
    View in: PubMed
    Score: 0.008
  53. Early Integrated Palliative Care Within a Surgical Oncology Clinic. JAMA Netw Open. 2023 11 01; 6(11):e2341928.
    View in: PubMed
    Score: 0.007
  54. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. J Clin Oncol. 2024 Feb 10; 42(5):500-506.
    View in: PubMed
    Score: 0.007
  55. Single center outcomes from parenchymal-sparing resections and microwave ablations for neuroendocrine tumor liver metastases. Am J Surg. 2024 Mar; 229:17-23.
    View in: PubMed
    Score: 0.007
  56. Doublet vs. Triplet Systemic Chemotherapy for High Grade Appendiceal Adenocarcinoma with Peritoneal Metastases. J Gastrointest Surg. 2023 11; 27(11):2560-2562.
    View in: PubMed
    Score: 0.007
  57. Role of Tumor-informed Personalized Circulating Tumor DNA Assay in Informing Recurrence in Patients With Peritoneal Metastases From Colorectal and High-grade Appendix Cancer Undergoing Curative-intent Surgery. Ann Surg. 2023 12 01; 278(6):925-931.
    View in: PubMed
    Score: 0.007
  58. PI3K Pathway Alterations in Peritoneal Metastases are Associated with Earlier Recurrence in Patients with Colorectal Cancer Undergoing Optimal Cytoreductive Surgery. Ann Surg Oncol. 2023 May; 30(5):3114-3122.
    View in: PubMed
    Score: 0.007
  59. Mutational profiles and prognostic impact in colorectal and high-grade appendiceal adenocarcinoma with peritoneal metastases. J Surg Oncol. 2023 Apr; 127(5):831-840.
    View in: PubMed
    Score: 0.007
  60. Intra-operative Radiation Therapy for Colorectal or Anal Cancer at Risk for Margin-Positive Resection: Initial Results of a Single-Institution Registry. Ann Surg Oncol. 2023 Jan; 30(1):325-332.
    View in: PubMed
    Score: 0.007
  61. Evaluating the Addition of Clinical and Staging Data to Improve the Pricing Methodology of the Oncology Care Model. JCO Oncol Pract. 2022 11; 18(11):e1899-e1907.
    View in: PubMed
    Score: 0.007
  62. Practice Considerations for Participation in the Enhancing Oncology Model. JCO Oncol Pract. 2022 11; 18(11):737-741.
    View in: PubMed
    Score: 0.007
  63. Survival in Total Preoperative vs. Perioperative Chemotherapy for Patients with Metastatic High-Grade Appendiceal Adenocarcinoma Undergoing CRS/HIPEC. J Gastrointest Surg. 2022 12; 26(12):2591-2594.
    View in: PubMed
    Score: 0.007
  64. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022 08 10; 40(23):2546-2556.
    View in: PubMed
    Score: 0.007
  65. Oncology alternative payment models: lessons from commercial insurance. Am J Manag Care. 2022 03; 28(3):98-100.
    View in: PubMed
    Score: 0.007
  66. Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. J Geriatr Oncol. 2022 05; 13(4):469-479.
    View in: PubMed
    Score: 0.007
  67. Celecoxib and Myrtol: A Novel Therapy for Recurrent Appendiceal Mucinous Neoplasms With Extensive Peritoneal Dissemination. Am J Clin Oncol. 2022 01 01; 45(1):9-13.
    View in: PubMed
    Score: 0.007
  68. Management of colorectal cancer during the COVID-19 pandemic: Recommendations from a statewide multidisciplinary cancer collaborative. J Surg Oncol. 2022 Mar; 125(4):560-563.
    View in: PubMed
    Score: 0.007
  69. Oncology Medical Home: ASCO and COA Standards. JCO Oncol Pract. 2021 08; 17(8):475-492.
    View in: PubMed
    Score: 0.006
  70. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.006
  71. Race and Gender Differences in Awareness of Colorectal Cancer Screening Tests and Guidelines Among Recently Diagnosed Colon Cancer Patients in an Urban Setting. J Cancer Educ. 2021 06; 36(3):567-575.
    View in: PubMed
    Score: 0.006
  72. Health Insurance Status as a Predictor of Mode of Colon Cancer Detection but Not Stage at Diagnosis: Implications for Early Detection. Public Health Rep. 2022 May-Jun; 137(3):479-487.
    View in: PubMed
    Score: 0.006
  73. Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy. Ann Surg Oncol. 2021 Aug; 28(8):4433-4443.
    View in: PubMed
    Score: 0.006
  74. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
    View in: PubMed
    Score: 0.006
  75. Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. JAMA Netw Open. 2020 10 01; 3(10):e2023500.
    View in: PubMed
    Score: 0.006
  76. Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma. Ann Surg Oncol. 2021 Mar; 28(3):1777-1785.
    View in: PubMed
    Score: 0.006
  77. IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectr. 2021 02; 5(1).
    View in: PubMed
    Score: 0.006
  78. Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies. Surgery. 2021 01; 169(1):162-167.
    View in: PubMed
    Score: 0.006
  79. Gender- and Race-Based Differences in Barriers and Facilitators to Early Detection of Colon Cancer. J Womens Health (Larchmt). 2020 09; 29(9):1192-1202.
    View in: PubMed
    Score: 0.006
  80. Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
    View in: PubMed
    Score: 0.006
  81. Facilities that service economically advantaged neighborhoods perform surgical metastasectomy more often for patients with colorectal liver metastases. Cancer. 2020 01 15; 126(2):281-292.
    View in: PubMed
    Score: 0.006
  82. Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clin Cancer Res. 2020 01 01; 26(1):18-24.
    View in: PubMed
    Score: 0.006
  83. Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Clin Oncol. 2019 10 10; 37(29):2620-2631.
    View in: PubMed
    Score: 0.006
  84. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer. JAMA Oncol. 2019 02 01; 5(2):236-242.
    View in: PubMed
    Score: 0.005
  85. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019 05 15; 125(10):1629-1636.
    View in: PubMed
    Score: 0.005
  86. Engaging Patients in Value-Based Cancer Care: A Missed Opportunity. JAMA Oncol. 2018 11 01; 4(11):1479-1480.
    View in: PubMed
    Score: 0.005
  87. Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial. Surgery. 2018 12; 164(6):1223-1229.
    View in: PubMed
    Score: 0.005
  88. Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. Dis Colon Rectum. 2018 Oct; 61(10):1146-1155.
    View in: PubMed
    Score: 0.005
  89. The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey. J Oncol Pract. 2018 07; 14(7):e412-e420.
    View in: PubMed
    Score: 0.005
  90. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
    View in: PubMed
    Score: 0.005
  91. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065.
    View in: PubMed
    Score: 0.005
  92. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol. 2018 Mar; 117(3):354-362.
    View in: PubMed
    Score: 0.005
  93. Examining racial disparities in colon cancer clinical delay in the Colon Cancer Patterns of Care in Chicago study. Ann Epidemiol. 2017 11; 27(11):731-738.e1.
    View in: PubMed
    Score: 0.005
  94. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 01; 8(1):37-48.
    View in: PubMed
    Score: 0.005
  95. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401.
    View in: PubMed
    Score: 0.005
  96. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.005
  97. Under-representation of peritoneal metastases in published clinical trials of metastatic colorectal cancer. Lancet Oncol. 2017 06; 18(6):711-712.
    View in: PubMed
    Score: 0.005
  98. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 04; 18(4):446-453.
    View in: PubMed
    Score: 0.005
  99. Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Feb 15; 23(4):918-924.
    View in: PubMed
    Score: 0.005
  100. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol. 2016 08 20; 34(24):2925-34.
    View in: PubMed
    Score: 0.004
  101. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics. 2016 Mar; 26(3):133-7.
    View in: PubMed
    Score: 0.004
  102. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9.
    View in: PubMed
    Score: 0.004
  103. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):957-66.
    View in: PubMed
    Score: 0.004
  104. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol. 2015 Aug 10; 33(23):2563-77.
    View in: PubMed
    Score: 0.004
  105. Combined-modality therapy for rectal cancer: analysis of potential differences in disease presentation, treatment adherence, and treatment outcome according to race. Am J Clin Oncol. 2014 Apr; 37(2):122-5.
    View in: PubMed
    Score: 0.004
  106. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15; 20(6):1666-75.
    View in: PubMed
    Score: 0.004
  107. The Vulnerable Elders Survey-13 predicts mortality in older adults with later-stage colorectal cancer receiving chemotherapy: a prospective pilot study. J Am Geriatr Soc. 2013 Nov; 61(11):2043-4.
    View in: PubMed
    Score: 0.004
  108. Qualitative analysis of practicing oncologists' attitudes and experiences regarding collection of patient-reported outcomes. J Oncol Pract. 2013 Nov; 9(6):e290-7.
    View in: PubMed
    Score: 0.004
  109. Eliminating racial disparities in colorectal cancer in the real world: it took a village. J Clin Oncol. 2013 Jun 01; 31(16):1928-30.
    View in: PubMed
    Score: 0.004
  110. Unsupported off-label chemotherapy in metastatic colon cancer. BMC Health Serv Res. 2012 Dec 29; 12:481.
    View in: PubMed
    Score: 0.004
  111. Infused chemotherapy use in the elderly after patent expiration. Am J Manag Care. 2012 May 01; 18(5):e173-8.
    View in: PubMed
    Score: 0.003
  112. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012 Apr 01; 18(7):2090-8.
    View in: PubMed
    Score: 0.003
  113. Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res. 2012 Jan 15; 18(2):350-9.
    View in: PubMed
    Score: 0.003
  114. American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. J Clin Oncol. 2011 Oct 01; 29(28):3816-24.
    View in: PubMed
    Score: 0.003
  115. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Jun; 30(3):1211-5.
    View in: PubMed
    Score: 0.003
  116. Value-based insurance design in oncology. Lancet Oncol. 2011 Apr; 12(4):321-3.
    View in: PubMed
    Score: 0.003
  117. Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. Clin Colorectal Cancer. 2010 Dec; 9(5):290-6.
    View in: PubMed
    Score: 0.003
  118. Predictors of competing mortality in early breast cancer. Cancer. 2010 Dec 01; 116(23):5365-73.
    View in: PubMed
    Score: 0.003
  119. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010 Jan 01; 28(1):15-20.
    View in: PubMed
    Score: 0.003
  120. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006 Nov 15; 98(22):1647-54.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.